KLK4 and COVID-19: The observed resurgence of oxygen need in some patients after icatibant may be due to icatibant’s short half life of about 2 hours.3 We propose that treatment strategies targeting the kallikrein-kinin system should be investigated in randomized trials for patients with COVID-19.